Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial.
Damask A, Steg PG, Schwartz GG, Szarek M, Hagström E, Badimon L, Chapman MJ, Boileau C, Tsimikas S, Ginsberg HN, Banerjee P, Manvelian G, Pordy R, Hess S, Overton JD, Lotta LA, Yancopoulos GD, Abecasis GR, Baras A, Paulding C; Regeneron Genetics Center and the ODYSSEY OUTCOMES Investigators. Damask A, et al. Among authors: tsimikas s. Circulation. 2020 Feb 25;141(8):624-636. doi: 10.1161/CIRCULATIONAHA.119.044434. Epub 2019 Nov 11. Circulation. 2020. PMID: 31707832 Clinical Trial.
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Tsimikas S, et al. Circulation. 2004 Sep 14;110(11):1406-12. doi: 10.1161/01.CIR.0000141728.23033.B5. Epub 2004 Sep 7. Circulation. 2004. PMID: 15353498 Clinical Trial.
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.
Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S. Merki E, et al. Among authors: tsimikas s. Circulation. 2008 Aug 12;118(7):743-53. doi: 10.1161/CIRCULATIONAHA.108.786822. Epub 2008 Jul 28. Circulation. 2008. PMID: 18663084
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators. Fraley AE, et al. Among authors: tsimikas s. J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96. doi: 10.1016/j.jacc.2009.02.041. J Am Coll Cardiol. 2009. PMID: 19497447 Free article. Clinical Trial.
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S; Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Trial Investigators. Ryu SK, et al. Among authors: tsimikas s. Circulation. 2012 Feb 14;125(6):757-66. doi: 10.1161/CIRCULATIONAHA.111.063487. Epub 2012 Jan 9. Circulation. 2012. PMID: 22230483
Lipoprotein(a) for risk assessment in patients with established coronary artery disease.
O'Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, Desai NR, Solomon SD, Domanski M, Arai K, Chiuve SE, Cannon CP, Sacks FM, Sabatine MS. O'Donoghue ML, et al. Among authors: tsimikas s. J Am Coll Cardiol. 2014 Feb 18;63(6):520-7. doi: 10.1016/j.jacc.2013.09.042. Epub 2013 Oct 23. J Am Coll Cardiol. 2014. PMID: 24161323 Free PMC article.
383 results